Trial
NCT04300309
Pharmacokinetics, Safety, Tolerability and Efficacy of a New Artemether-lumefantrine Dispersible Tablet in Infants and Neonates <5 kg Body Weight With Acute Uncomplicated Plasmodium Falciparum Malaria
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Novartis Pharmaceuticals
Collaborators
European and Developing Countries Clinical Trials Partnership (EDCTP); Medicines for Malaria Venture; Groupe de Recherche Action en Sante; Institut de Recherche en Sciences de la Sante, Burkina Faso
Condition
Plasmodium Falciparum Malaria
Intervention
artemether:lumefantrine (2.5 mg:30 mg)
Why stopped
Sponsor decision
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-01-13